# Pharma Q2 Outlook: Pricing Pressure and US Competition

> India's pharma giants face mixed Q2 results as pricing pressures and US competition reshape their outlook.
- Title: Pharma Q2 Outlook: Pricing Pressure and US Competition
- Summary: India's pharma giants face mixed Q2 results as pricing pressures and US competition reshape their outlook. India's pharmaceutical companies report mixed Q2…
- Keywords: india pharmaceutical companies, sun pharmaceutical industries, aurobindo pharma, torrent pharmaceuticals, divi's laboratories, dr reddy's laboratories, lupin, cipla, q2 outlook, pricing pressure, us competition, money
- Source: The Economic Times — https://economictimes.indiatimes.com/markets/stocks/earnings/indias-pharmaceutical-companies-to-report-mixed-results-as-domestic-growth-offsets-pricing-pressures/articleshow/135037267.cms
- Author: Snehal Mergu
- Published: 2026-10-19T00:29:00+00:00
- Read time: 1 min
- Topics: india pharmaceutical companies, sun pharmaceutical industries, aurobindo pharma, torrent pharmaceuticals, divi's laboratories, dr reddy's laboratories, lupin, cipla, q2 outlook, pricing pressure, us competition, money
## Q2 Performance Forecast
India's pharmaceutical companies report mixed Q2 results with domestic growth offsetting pricing pressures and US competition.
## Strong Performers
Sun Pharmaceutical Industries, Aurobindo Pharma, Torrent Pharmaceuticals and Divi's Laboratories are expected to be among the stronger performers.
## Pressure Points
Dr Reddy's Laboratories, Lupin and Cipla may face pressure due to absent high-margin opportunities and increased competition in key products.
## Sun Pharma Growth
Sun Pharma expects high-single-digit revenue growth from India, emerging markets and specialty products like Leqselvi, Unloxcyt, and Winlevi.
## Aurobindo Pharma
Aurobindo Pharma's revenue growth is led by Lannett acquisition, strong European performance and stable US business with double-digit EBITDA growth.
## Dr Reddy's Challenges
Dr Reddy's revenue remains flat as North America weakness offsets growth in other markets, with key monitorables including semaglutide supply restoration.
## Lupin and Cipla
Lupin expects high-single-digit revenue growth from India and non-US markets, while Cipla faces flat revenue despite strong Indian growth due to US business challenges.
## Torrent Pharma
Torrent Pharma's revenue growth is strongest among peers following JB Pharma consolidation with healthy core business growth in India and US.
## Divi's Laboratories
Divi's Laboratories' revenue driven by custom synthesis business, nutraceuticals growth, and iodine-based contrast media scale-up.
## Key takeaway

India's pharmaceutical companies report mixed Q2 performance with domestic growth offsetting pricing pressures and US competition.